New Chiral Stationary Phase

本项目的总体目标是开发新型、高性能的手性分离固定相。这些相是由约50摩尔%交联剂和50摩尔%手性选择剂组成的共聚物。它们基于Fenris Technology Research，Inc.开发的新型共聚物相。这些新材料已证明色谱效率相当于反相模式下的硅基相，甚至更好地用于苯胺的正相分离。它们将结合联合收割机的高效率和高容量的手性分离。第一阶段的目标是确认新的手性固定相的预期优势。手性选择剂将是脯氨酸-芳族胺缀合物，其已被证明提供高手性选择性。新阶段的性能将与现有的商业阶段进行比较。关键实验将是测量对映异构体分离度作为新相和商业相上相同溶质的外消旋体进样量的函数。通过证明新的手性固定相可以分离至少两倍于同等尺寸和粒度的竞争商业柱的外消旋体，并具有令人满意的分离度，将确立I期可行性。拟议的商业应用：光学纯异构体的分离和离析。这对于涉及对映体药物的制药工业是极其重要的。光学纯的药物是有效的，没有其他对映体的副作用。

The overall goal of this project is to develop new, high performance stationary phases for chiral separations. These phases are copolymers consisting of approximately 50 mole-% crosslinker and 50 mole-% chiral selectors. They are based on new co-polymer phases developed by Fenris Technology Research, Inc. These new materials have demonstrated chromatographic efficiencies that are equivalent to silica based phases in the reversed phase mode and even better for the normal phase separation of aniline. They will combine high efficiency and high capacity for chiral separations. The Phase I goal is to confirm the expected advantages of new chiral stationary phase. The chiral selector will be a proline-aromatic amine conjugate that has been demonstrated to provide high chiral selectivity. The performance of the new phase will be compared to existing commercial phases. The key experiment will be to measure enantiomer resolution as a function of he amount of injected racemate for the same solute on both the new phase and commercial phases. Phase I feasibility will be established by showing the new chiral stationary phase can separate at least twice as much racemate with satisfactory resolution as competing commercial columns of equivalent dimensions and particle size. PROPOSED COMMERCIAL APPLICATIONS: Separation and isolation of optically pure isomers. This is extremely important to the pharmaceutical industry where enantiomeric drugs are involved. Optically pure drugs are effective without the side effects of the other enantiomer.